Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma
- Published
- Accepted
- Received
- Academic Editor
- Jianye Ge
- Subject Areas
- Bioinformatics, Hematology, Oncology, Medical Genetics, COVID-19
- Keywords
- Diffuse large B-cell lymphoma, Integrated bioinformatic analysis, Hub genes, Ribosome, COVID-19, Immune cells
- Copyright
- © 2021 Charwudzi et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
- Cite this article
- 2021. Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma. PeerJ 9:e12394 https://doi.org/10.7717/peerj.12394
Abstract
Background
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy with varied outcomes. However, the fundamental mechanisms remain to be fully defined.
Aim
We aimed to identify core differentially co-expressed hub genes and perturbed pathways relevant to the pathogenesis and prognosis of DLBCL.
Methods
We retrieved the raw gene expression profile and clinical information of GSE12453 from the Gene Expression Omnibus (GEO) database. We used integrated bioinformatics analysis to identify differentially co-expressed genes. The CIBERSORT analysis was also applied to predict tumor-infiltrating immune cells (TIICs) in the GSE12453 dataset. We performed survival and ssGSEA (single-sample Gene Set Enrichment Analysis) (for TIICs) analyses and validated the hub genes using GEPIA2 and an independent GSE31312 dataset.
Results
We identified 46 differentially co-expressed hub genes in the GSE12453 dataset. Gene expression levels and survival analysis found 15 differentially co-expressed core hub genes. The core genes prognostic values and expression levels were further validated in the GEPIA2 database and GSE31312 dataset to be reliable (p < 0.01). The core genes’ main KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichments were Ribosome and Coronavirus disease-COVID-19. High expressions of the 15 core hub genes had prognostic value in DLBCL. The core genes showed significant predictive accuracy in distinguishing DLBCL cases from non-tumor controls, with the area under the curve (AUC) ranging from 0.992 to 1.00. Finally, CIBERSORT analysis on GSE12453 revealed immune cells, including activated memory CD4+ T cells and M0, M1, and M2-macrophages as the infiltrates in the DLBCL microenvironment.
Conclusion
Our study found differentially co-expressed core hub genes and relevant pathways involved in ribosome and COVID-19 disease that may be potential targets for prognosis and novel therapeutic intervention in DLBCL.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is exceptionally heterogeneous and the most common aggressive non-Hodgkin lymphoma (NHL) subtype in adults. It is increasingly appreciated that its varied outcomes depend on the patients’ clinical and biological features (Karube et al., 2018; Liu et al., 2019b; Luo et al., 2018; Naresh et al., 2011). Despite several reports on the mechanism of DLBCL, its pathogenesis characterized by multiple abnormalities at different molecular levels remains unresolved. Its development and progression are multifaceted, comprising various signaling pathways and driver genes. Despite improved clinical outcomes with current therapies, such as rituximab-chemotherapy (R-CHOP), chimeric antigen receptor (CAR)-T cell, and advancement in stem cell transplantation, over 40% of high-risk patients relapse or develop the primary refractory disease. Mortality figures remain high (Karube et al., 2018; Luo et al., 2018). Therefore, an in-depth understanding of disease biology could reveal novel biomarkers of diagnostic and prognostic value. It will also facilitate the design of alternative personalized therapeutic strategies for DLBCL.
Advances in gene profiling technologies, high-throughput data, and bioinformatics databases make screening DLBCL for differentially co-expressed genes indispensable, particularly when integrated with personalized genomic profile data (Lui et al., 2015; van Dam et al., 2018). Recently, Liu et al. (2019a) identified eleven genes associated with endometrial cancer progression and prognosis by comprehensive bioinformatics analysis. Zhou et al. (2019) used CIBERSORT and other bioinformatics analyses for colon cancer. They found that the tumor microenvironment (TME) was abundantly enriched with M0 and M2 macrophages, activated memory CD4+ T cells, and other immune cells that could play crucial roles as biomarkers (Zhou et al., 2019). However, few integrated bioinformatics studies have compared the gene expression profile of DLBCL with non-cancer controls.
Thus, we downloaded the Gene Expression Omnibus (GEO) raw dataset of GSE12453 and compared 11 DLBCL cases with 24 non-cancer controls (non-neoplastic B lymphocytes isolated from blood or tonsils). We performed a series of screens and analyses, including filtering off differentially expressed genes (DEGs), enrichment analysis, and co-expression analysis to determine hub genes of clinical significance to DLBCL. We identified 15 differentially co-expressed core hub genes associated with the prognosis of DLBCL (RPS24, RPS21, RPL31, RPL30, RPS17, MRPS28, FAU, RPS25, RPL22L1, NDUFA6, CXCL9, CCL4, MRPL33, HEBP1, and RPL11). The KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis associated most of the genes with Ribosome and Coronavirus disease-COVID-19 pathways. Validation in the GEPIA2 database and GSE31312 dataset revealed that the core genes had consistent expression levels and were reliable. Receiver operating characteristic (ROC) curves plotted demonstrated that the core genes could be potential diagnostic biomarkers. The identified genes could play critical roles in diagnosis, prognosis, and help establish a foundation for developing or identifying novel targeted therapies for DLBCL.
Materials and Methods
Data collection
We evaluated and downloaded the raw gene expression profiles from the National Center for Biotechnology Information-Gene Expression Omnibus (NCBI-GEO) database (https://www.ncbi.nlm.nih.gov/geo/). The series was based on GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. GSE12453 (Brune et al., 2008) was used to identify differentially expressed and co-expressed genes. It was also used to predict tumor-infiltrating immune cells (TIICs). It contained 11 DLBCL cases and 25 normal controls. The controls were non-neoplastic B lymphocytes isolated from healthy donors’ blood or tonsils from routine tonsillectomy patients. Similar expression profiles on the selected GPL570 platform contained normal but reactive controls or non-human controls, such as cell lines or limited controls, and were excluded. We used the GSE31312 (Visco et al., 2012) with 498 DLBCL cases for survival analysis and identifying immune cells infiltrating the TME.
Study design and data pre-processing
The GSE12453 CEL file was pre-processed using the Affymetrix package (Gautier et al., 2004) in R software (https://www.r-project.org/) version 4.0.2 (Team, 2019). The procedures included background correction, log2 transformation, followed by quantile normalization. We performed a standard quality assessment, including scaling factors and NUSE plots, and hierarchical clustering to identify outliers. The study’s design flowchart is shown in Fig S1.
Screening of differentially expressed genes (DEGs)
The DEGs between DLBCL cases and non-cancer controls were screened with R package limma (https://www.bioconductor.org/), Release 3.11 (Ritchie et al., 2015). The cutoff criteria were p < 0.05, |log2fold change (FC)| > 1.0. The pheatmap package was used to generate hierarchical clustering, and ggplot2 (Wickham, 2016) was used to show the volcano plot in R. We used the resulting data output tables that included gene ID, log2FC, unadjusted and adjusted p-values in subsequent analyses.
Functional and pathway enrichment analysis
We investigated the functional roles and pathway signaling relevance of the DEGs. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed using the R clusterprofiler (https://bioconductor.org/), Release 3.12 (Yu et al., 2012). A p-value < 0.05 was considered significantly enriched. The GO categories included biological process (BP), molecular function (MF), and cellular component (CC).
Gene set enrichment analysis (GSEA)
We used the normalized expression dataset of GSE12453 for the GSEA (www.gsea-msigdb.org/gsea/index.jsp), version 4.1.0. We followed the recommended protocol. This included “gct” and “cls” file formats for the expression dataset and phenotype labels, respectively (Subramanian et al., 2005). Significant gene sets had a false discovery rate (FDR) <0.25 and a nominal p-value < 0.05.
Protein-protein interaction (PPI) network of DEGs and hub modules selection
We applied the STRING database (https://string-db.org), version 11.0 (Szklarczyk et al., 2019), to assess and map the identified DEGs into a human PPI network. Then, we uploaded the resulting data output into Cytoscape software (https://cytoscape.org/), version 3.8.2 (Shannon et al., 2003), and used MCODE with default parameters (Bader & Hogue, 2003) and the Cytohubba (Chin et al., 2014) plug-ins to select significant modules and top-ranked genes. Nodes and edges represented genes and their interactions.
Predicting tumor-infiltrating immune cells (TIICs)
We applied the Cibersort algorithm (Newman et al., 2019) in R to predict TIICs using the normalized GSE12453 dataset, according to the CIBERSORT instructions. We used data with a p-value < 0.05 for further analysis.
Co-expression network construction and identification of modules related to DLBCL
We conducted gene co-expression analysis on the processed GSE12453 data using the weighted correlation network analysis (WGCNA) (Langfelder & Horvath, 2008; Langfelder & Horvath, 2012) in R (Team, 2019). We followed the standard protocols, including quality control procedures. We performed a power β transformation on the computed Pearson correlation matrix to ensure a scale-free topology. The minimum number of module genes was set at 30. The WGCNA R package then generated a co-expression network from the resulting adjacency matrix. We applied the dynamic Tree Cut package (Team, 2019) to create the co-expression modules from the color-coded hierarchical clustering dendrogram. We assessed clinical module-trait relationships with Pearson’s correlation. Gene significance (GS) and module membership (MM) were also analyzed for their correlation in modules. Statistically significant modules were defined as p < 0.05.
Identifying differentially co-expressed hub module genes
The hub genes were identified from the intersection between the DEGs and genes significant in the WGCNA modules. We then analyzed the hub genes with the STRING and Cytoscape databases. We further conducted functional and pathway analysis on the hub genes to determine the relevant genes that impact DLBCL.
Validation and survival analysis of core hub genes
We validated the expression levels of the hub genes in the GEPIA2 (gepia2.cancer-pku.cn/#index) database (Tang et al., 2019). We retrieved the pre-processed quantile normalized series matrix file (GSE31312, Affymetrix HG-U133 Plus 2.0 GeneChips) containing 498 de-novo adults DLBCL from the NCBI-GEO database. We used it for the prognostic value analysis (overall survival (OS) and progression-free survival (PFS)). We plotted Kaplan–Meier survival curves with ggplot2 in R. The genes with p-value < 0.05 were selected as core hub genes. Also, receiver operating characteristic (ROC) curves were plotted with the pROC R package (Team, 2019) to validate the diagnostic value of the core genes. Then, the human protein atlas (proteinatlas.org/) was used to confirm their protein expressions in some selected lymph node samples (Uhlen et al., 2017).
We used the ssGSEA (single-sample Gene Set Enrichment Analysis) package (Subramanian et al., 2005) in R on the GSE31312 dataset to investigate immune-associated core hub genes in the TME.
In addition, we also employed the GEPIA2 and Oncomine (Rhodes et al., 2004) databases to determine the expression levels and relevance of the core hub genes in other tumors.
Results
Differentially expressed genes (DEGs)
According to standard protocols, one poor quality control sample (GSM312887) was excluded from the GSE12453 dataset after pre-processing. We identified 1,260 DEGs between the 11 DLBCL and 24 non-tumor controls. They comprised 1,014 up-regulated and 246 down-regulated genes (p < 0.05 and |log2FC| > 1). The gene list, Affymetrix probe ID, and log FC are shown in (Excel S1). The expression patterns of the DEGs are shown in Fig. 1. Figure 1A shows the volcano plot of all expressed genes. The DLBCL cases showed a distinctive gene expression profiling. As shown in Fig. 1B, the heatmap of the top 169 DEGs with |log2FC| > 2 suggested that the identified DEGs expression levels could differentiate DLBCL from non-tumor samples. We utilized the CytoHubba application in Cytoscape, employing five calculation methods: the Maximal Clique Centrality (MCC), Maximum Neighborhood Component (MNC), Degree, Edge Percolation Component (EPC), and EcCentricity to rank the top 250 DEGs. The genes from the five methods were intersected using the Venn diagram software (http://bioinformatics.psb.ugent.be/webtools/Venn/). Most of the intersecting genes (Fig. 1C) were associated with significant and valuable pathways such as the proteasome, spliceosome, and viral protein interaction with cytokine and cytokine receptor (Fig. S2). Intersecting genes are common genes with a high degree of interconnection and are more likely to represent key candidate genes with important biological regulatory functions.
Functional and pathway analysis
We applied the enrichGO or enrichKEGG function of the clusterProfiler package (Yu et al., 2012) in R to investigate the biological functions of all the DEGs (p < 0.05). The GO and KEGG pathway analysis results are shown in Fig. 2. In GO analysis, the DEGs were primarily enriched in ATP synthesis coupled electron transport and mitochondria ATP synthesis coupled electron transport for biological processes (BP). Their cellular components (CC) were mainly related to the mitochondria protein complex, mitochondria inner membrane, etc. Their molecular functions (MF) consisted of structural constituents of ribosomes and NADH dehydrogenase activity (Fig. 2A). The KEGG pathway analysis showed significant enrichment in ribosome and oxidative phosphorylation (Fig. 2B). Strikingly, the DEGs involved in the KEGG pathway and GO enrichment analysis were mainly upregulated genes, with few down-regulated genes.
Further analysis showed that the down-regulated genes were enriched in B cell activation (adjust p-value = 0.003) for GO-BP; our data showed no other significant GO and KEGG enrichment for the down-regulated genes. The GO and KEGG enrichment analysis for the upregulated genes was similar to the analysis we performed earlier. The GO and KEGG analysis classifies genes into functional categories to help understand their functions and regulatory pathways. Hence, with additional investigations, the genes in these pathways might throw more light on the pathogenesis of DLBCL.
Gene Set Enrichment Analysis (GSEA) of DLBCL expression dataset (GSE12453)
We performed a GSEA analysis to compare the DLBCL and non-tumor controls’ expression profiles to understand better the biological functions of the relevant genes discovered. We analyzed all the qualified genes in the GSE12453 expression dataset. The KEGG output from the GSEA was similar to our previous pathway analysis and confirmed our earlier results. The Hallmark gene sets showed immune and metabolic-related signaling predominance, including estrogen response late, epithelial-mesenchymal transition, and UV response up (Table S1). Interestingly, genes defining late response to estrogen, epithelial-mesenchymal transition (such as in fibrosis and metastasis), and genes upregulated in response to ultraviolet (UV) radiation have not been fully elucidated in DLBCL. However, evidence suggests these genes have essential roles in oncogenesis. These findings provide evidence that can drive future research with therapeutic implications.
Predicting tumor-infiltrating immune cells (TIICs)
Our GO, KEGG, and GSEA analyses showed that the DEGs were enriched in some immune-related biological functions. Immune cell infiltration into tumors plays an essential role in tumorigenesis and metastasis. So, we applied the CIBERSORT algorithm to the GSE12453 dataset to predict immune cells infiltrating the TME. Among the immune subsets analyzed, activated memory CD4+ T cells, CD8+ T cells, and M0, M1, and M2 macrophages were the most represented cell fractions within the DLBCL microenvironment (Figs. 3A, 3B). The correlations among the TIICs ranged from high to negligible (Fig. S3). Regulatory T cells (Tregs) showed a moderate negative correlation with activated memory CD4+ T cells. However, M0 macrophages had a high positive correlation with activated memory CD4+ T cells and M1 macrophages. The varied infiltrating immune cell types could be reflective of the complexity and the unusual behavior of DLBCL. Uncommitted macrophages (M0) can polarize into the M1 (considered tumoricidal) and M2 (pro-tumorigenic) to show paradox effects on tumor prognosis (Dancsok et al., 2020). Memory B cells and activated dendritic cells were the most represented fractions in the non-tumor controls (Fig. 3A). The findings suggest that TIICs may be closely associated with clinical outcomes. Future studies, including their correlation to DLBCL disease stages, will be meaningful, particularly for immunotherapy.
Protein-protein interaction (PPI) network and hub modules establishment
We constructed the PPI network of all DEGs using the STRING database’s multiple proteins function to determine genes likely to perform biological functions together. The highest confidence of 0.9 was set with unconnected nodes taken out. As shown in Fig. 4A, it yielded 609 nodes and 8,583 edges. These genes were highly inter-connected than expected (PPI enrichment p-value < 1.0e−16). We observed six important clusters with a k-score > 10 when we analyzed the tab-separated values (tsv) file with Cytoscape’s MCODE. The largest cluster (#1) had the highest score of 33.17 (Fig. 4B); it mainly comprised Ribosome genes (FDR = 3.49e−83) in KEGG analysis. Cluster 2 (Fig. 4C) was enriched in genes associated with oxidative phosphorylation (FDR, 7.23e−56) and Parkinson’s disease (FDR, 2.62e−55). Cluster three (Fig. 4D) genes were mainly involved in chemokine signaling (FDR, 1.06e−22). We identified 109 highly connected DEGs (Excel S1) from these top three clusters. These DEGs could play essential roles in DLBCL, so they were selected for further hub gene screening.
In this study, the down-regulated DEGs were not part of the constructed PPI, so we determined their relevance in DLBCL. We ranked the top 60 DEGs (30 up-and 30 down-regulated) by log2FC and analyzed them in the STRING database (Fig. S4A). The only down-regulated DEG in the network built was identified upregulated when verified in the GEPIA2 database. To further investigate the down-regulated DEGs’ functional relatedness, a PPI was constructed for all the down-regulated DEGs (Fig. S4B). We found that the down-regulated genes were enriched in B cell activation for GO-BP, shown in (Fig. S4C). Finally, we used the degree method of the CytoHubba application to predict the top 250 important genes (Fig. 4E). Genes with a high degree of centrality are vital since they have many direct interacting gene partners. If confirmed, these critical findings could improve the general understanding and the potential causes of variation in the clinical prognosis of DLBCL.
Weighted gene co-expression network (WGCNA) analysis
To identify co-expression modules that could share similar biological functions or regulatory mechanisms with clinical relevance to DLBCL, we applied the WGCNA package (Langfelder & Horvath, 2008; Langfelder & Horvath, 2012) in R (Team, 2019). The GSE12453 dataset we processed was used. We carried out quality control procedures, including inspecting good genes and sample hierarchical clustering to detect potential outliers, but no obvious outliers were found (Fig. 5A). The 35 samples yielded two main clusters. We applied the WGCNA on the top 25% of the 21,654 expressed genes ranked by the largest variance. To satisfy a scale-free network topology, we choose the soft-threshold power β of eight with R2 = 0.86 (Figs. 5B, 5C). Hierarchical clustering and the dynamic tree-cutting yielded 18 modules of co-expressed genes (Fig. 5D). Finally, we visualized the top 1,000 significantly expressed genes with a heatmap (Fig. 5E); they represent interesting genes for further analysis.
To investigate the molecular mechanisms of the traits, we correlated each Module Eigengenes (ME) to disease status (DLBCL and non-tumor controls). The results are shown in Fig. 6. The ME turquoise and green (Figs. 6A, 6B) containing 292 and 72 genes, respectively, strongly correlated with DLBCL. ME dark magenta with five genes had the strongest negative correlation. The cut-off was set at gene significance (GS) value >0.8, and absolute Module Membership (MM) value >0.7. Besides, the GS versus MM plots for these three modules were highly correlated (Fig. 6C), reflecting their high association with DLBCL. We selected these three clinically significant modules with the 369 high connectivity genes (gene list shown in Excel S1) for further analysis. The highly connected genes are often the most important (central) elements of the respective modules and tend to play key roles in the biological processes. The ME genes are listed in Excel S1. Altogether, these co-expressed genes might provide new clues to understand the biology of DLBCL in the future.
PPI and functional enrichment analysis of the WGCNA relevant modules
The 369 high connectivity genes from the three relevant modules were filtered in the STRING database followed by the Cytoscape; the network yielded a PPI with 195 nodes and 1,579 edges. The PPI and gene list are detailed in Fig. S5 and Excel S1. These 195 genes were considered functionally important. As presented in (Fig. 7), functional annotation revealed that these genes were involved in viral transcription and viral gene expression in the BP category. In KEGG analysis, the genes were primarily enriched in ribosome, coronavirus disease-COVID-19, and oxidative phosphorylation. The identified pathways were roughly consistent with that of the DEGs. These processes and signaling pathways are usually disrupted in cancer and could provide an insight into the pathogenesis of DLBCL.
Identification of hub genes and pathways
Eventually, we identified 46 important differentially co-expressed genes by the Venn diagram software, as shown in (Fig. 8A). These 46 genes were common between the DEGs and WGCNA hub module genes and were regarded as hub genes. We re-analyzed the 46 genes with the STRING and Cytoscape databases, and the PPI is shown in (Fig. 8B). Their GO and KEGG enrichments in the R software (Table 1) were similar to the other analyses. The KEGG common genes in the ribosome, COVID-19, and oxidative phosphorylation pathways are shown in Table 2. The above pathway genes play essential roles in metabolic reprogramming and tumor-promoting inflammation of cancer and warrant further studies.
Term | Description | Count | p. adjust |
---|---|---|---|
Biological process | |||
GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 16 | 1.29E−22 |
GO:0019083 | Viral transcription | 18 | 1.29E−22 |
GO:0006613 | Cotranslational protein targeting to membrane | 16 | 1.29E−22 |
GO:0019080 | Viral gene expression | 18 | 2.85E−22 |
GO:0045047 | Protein targeting to ER | 16 | 2.98E−22 |
GO:0000184 | Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 16 | 3.30E−22 |
GO:0072599 | Establishment of protein localization to endoplasmic reticulum | 16 | 3.74E−22 |
GO:0070972 | Protein localization to endoplasmic reticulum | 16 | 7.45E−21 |
Cellular component | |||
GO:0044391 | Ribosomal subunit | 25 | 2.39E−37 |
GO:0005840 | Ribosome | 25 | 1.45E−33 |
GO:0022626 | Cytosolic ribosome | 18 | 3.96E−28 |
GO:0015934 | Large ribosomal subunit | 17 | 1.54E−25 |
GO:0044445 | Cytosolic part | 18 | 6.76E−22 |
GO:0098798 | Mitochondrial protein complex | 17 | 8.16E−20 |
GO:0005743 | Mitochondrial inner membrane | 19 | 2.01E−18 |
GO:0022625 | Cytosolic large ribosomal subunit | 11 | 1.14E−17 |
Molecular function | |||
GO:0003735 | Structural constituent of ribosome | 24 | 1.15E−33 |
GO:0003954 | NADH dehydrogenase activity | 9 | 3.12E−14 |
GO:0008137 | NADH dehydrogenase (ubiquinone) activity | 9 | 3.12E−14 |
GO:0050136 | NADH dehydrogenase (quinone) activity | 9 | 3.12E−14 |
GO:0016655 | Oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor | 9 | 3.26E−13 |
GO:0016651 | Oxidoreductase activity, acting on NAD(P)H | 9 | 6.05E−11 |
GO:0008009 | Chemokine activity | 6 | 2.25E−08 |
KEGG pathway | |||
hsa03010 | Ribosome | 24 | 4.36E−29 |
hsa05171 | Coronavirus disease-COVID-19 | 21 | 2.35E−20 |
hsa00190 | Oxidative phosphorylation | 11 | 9.15E−10 |
Note:
The selection of terms enriched in the categories was based on the most significant adjusted p-value (p. adjust). Count: the number of genes enriched in each term or pathway.
S/N | 24 differentially co-expressed (DCE) ribosome genes | 21 DCE coronavirus disease-COVID-19 | 11 differentially co-expressed oxidative phosphorylation genes |
---|---|---|---|
1 | MRPS18A | RPL10L | UQCRQ |
2 | RPL10L | RPL24 | NDUFB1 |
3 | MRPL17 | RPS17 | NDUFB2 |
4 | RPL24 | CXCL10 | NDUFB3 |
5 | RPS17 | RPL30 | NDUFS6 |
6 | RPL30 | RPS18 | NDUFA1 |
7 | RPS18 | C3 | NDUFA3 |
8 | RPS19 | RPS19 | NDUFA11 |
9 | RPL29 | RPL29 | NDUFB9 |
10 | RPL31 | RPL31 | NDUFA6 |
11 | RPL36 | RPL36 | UQCR11 |
12 | MRPL33 | RPS21 | |
13 | RPS21 | FAU | |
14 | MRPL21 | RPS24 | |
15 | FAU | RPL14 | |
16 | RPS24 | RPS25 | |
17 | RPL14 | RPL22L1 | |
18 | RPS25 | RPL11 | |
19 | RPL22L1 | RPL35 | |
20 | RPL35 | RPL12 | |
21 | MRPL14 | RPS7 | |
22 | RPL11 | ||
23 | RPL12 | ||
24 | RPS7 |
Note:
DCE, differentially co-expressed.
Validation of expressions and prognostic analysis of core hub genes
We applied GEPIA2 to validate the reliability and authenticity of the 46 hub genes in the cancer genome atlas (TCGA) dataset. We identified 44 prognostic genes with higher expression (consistent with that in the GSE12453 dataset) in DLBCL tissues than the non-tumor control tissues (p < 0.01) (Fig. 9) (15 genes shown) and (Excel S1). Kaplan–Meier survival analysis on the GSE31312 showed 15 of these genes (p < 0.05) correlated with patient outcomes (Fig. 10 & Table S2). Except for RPL11, the patients with high expressions had significantly shorter 5-year OS and PFS, suggesting these genes are potential oncogenes and have a role in DLBCL development and/or progression. The 15 genes (Fig. 11A) were considered as the core hub genes. Moreover, ROC curve analysis for their diagnostic potentials obtained AUCs ranging from 0.992 to 1.00, indicating optimal performance to accurately differentiate DLBCL from non-tumor control cases (Fig. S6). Also, immunohistochemistry data from the human protein atlas (HPA) database demonstrated the protein expressions of some of the genes in some lymph node samples with cytoplasmic/membranous localization (Fig. S7, four genes shown); data were retrieved from https://www.proteinatlas. The genes included RPS21, MRPS28, RPL31, and RPL30. As expected, they would be involved in metabolic pathways such as glycolysis and processes including signal transduction and cell division.
The core hub genes’ functional annotation was mainly associated with Ribosome and Coronavirus disease-COVID-19 (Figs. 11B, 11C; Table 3). To assess the tumorigenic potentials of the COVID-19 genes regarding immune cells infiltrating the TME, the ssGSEA analysis was applied (GSE31312). As shown in Fig. S8, seven out of the nine COVID-19 pathway genes negatively correlated with mast cells, five with immature dendritic cell (iDC), and three genes negatively correlated with plasmacytoid DC. RPL30, RPL31, RPS25, and FAU positively correlated with tumor-infiltrating lymphocytes (TIL) and macrophages. RPL30, RPL31 correlated with Tregs. These infiltrating immune cells may be involved in regulating tumor proliferation, dormancy, and drug resistance.
KEGG pathway | Number of genes | List of genes | p. adjust |
---|---|---|---|
hsa03010: Ribosome | 10 | RPS24/RPS21/RPL31/RPL30/RPS17/FAU/RPS25/RPL22L1/MRPL33/RPL11 | 3.12E-14 |
hsa05171: Coronavirus disease-COVID-19 | 9 | RPS24/RPS21/RPL31/RPL30/RPS17/FAU/RPS25/RPL22L1/RPL11 | 6.89E-11 |
hsa04061: Viral protein interaction with cytokine and cytokine receptor | 2 | CXCL9/CCL4 | 0.0552 |
Finally, we determined whether the core genes were upregulated in other tumors. The GEPIA2 database revealed that all the 15 core genes were upregulated in thymoma (THYM), and 11 genes were upregulated in testicular germ cell tumors (TGCT). Notably, RPL30 and FAU genes were consistently upregulated in all six different cancer types identified (Table S3). In the Oncomine database, some of the core genes were upregulated in various lymphoma datasets and other cancers, including Sarcoma (Fig. S9). The results suggest that the upregulation of these 15 hub genes may not be limited to DLBCL.
Discussion
Diffuse large B-cell lymphoma (DLBCL) remains a significant clinical challenge; over 30% of patients are not cured (Pasqualucci & Dalla-Favera, 2018; Yi et al., 2020). So far, no functional assays capable of screening exit, so effective management is required once diagnosed. Hence, identifying unique gene signatures and regulatory pathways related to its pathogenesis and prognosis is meaningful. Here, we examined the gene expression profile of GSE12453 to find dysregulated common core hub genes and pathways to help further understand DLBCL pathogenesis and provide potential biomarkers.
Integrated bioinformatics analysis, gene expression levels, and survival analysis identified 15 differentially co-expressed core hub genes linked to DLBCL pathogenesis. The genes included RPS24, RPS21, RPL31, RPL30, RPS17, MRPS28, FAU, RPS25, RPL22L1, NDUFA6, CXCL9, CCL4, MRPL33, HEBP1, and RPL11. Their primary KEGG enrichment was ribosome and coronavirus disease-COVID-19, which was in line with the other analyses. The construction of ROC curves yielded very high AUC values suggesting the genes could accurately distinguish between DLBCL and non-tumor control cases and might be potential biomarkers. In addition, experimentally derived data from the HPA by IHC indicated the protein expression of some of the genes in some lymph node samples. RPS21, MRPS28, RPL31, and RPL30 showed relatively higher protein expressions in some DLBCL and other malignant lymphoma tissues than the averaged expressions in normal tissues, though not significant. The HPA database sample size was limited; however, the HPA experimental findings can be extended to DLBCL and other lymphomas, thus providing a valuable basis for medical and biological research.
Lastly, most of the core genes were upregulated in different cancer types. Cancer is a complex disease, so the genes might have similar or different prognostic roles in these tumors. The overall survival data from GEPIA2 demonstrated that low levels of FAU, RPS17, and RPS 24 were significantly associated with shorter survival, while high CCL4 was significantly associated with shorter survival in thymoma patients. Nonetheless, the genes’ potential biological and clinical relevance is not restricted to only DLBCL. These genes could be prognostic markers and therapeutic targets across different tumor types, particularly for patients with multiple coexisting tumors.
Little is known experimentally about the roles of most of the core genes proteins in DLBCL. However, dysregulated ribosomal proteins have been reported to play various critical roles in other tumors (Wang et al., 2015). Among our ribosome genes, over-expressed RPS21 promoted prostate cancer (PCa) cell proliferation, migration, and invasion, inhibited PCa cell apoptosis, and was suggested as a promising biomarker, with a potential application in diagnosis or treatment (Liang et al., 2019). The 8q-mapped RPL30 gene was associated with adverse outcomes in Medulloblastoma patients (De Bortoli et al., 2006). RPS24 significantly promoted colorectal cancer (CRC) cells’ proliferation rate and increased CRC risk in patients (Zou et al., 2020). The knockdown of RPS24 inhibited cell proliferation and cell migration in human CRC cell lines and was recommended as a biomarker (Wang et al., 2015). A study also implicated MRPS28 in the molecular pathogenesis of bladder cancer (Liu et al., 2021).
The coronavirus disease-COVID-19 and viral transcription enrichments agree with recent studies implicating various viruses (Gandhi et al., 2020) (Fedoriw et al., 2020) in the development and progression of DLBCL subtypes. Most DLBCL patients have an underlying immune dysfunction and can easily get viral infections. Viruses such as COVID 19 could manipulate the function of the COVID 19 related genes in the TME. Besides, the Gene Cards database (https://www.genecards.org/) demonstrated all the covid 19 pathway genes (RPS24, RPS21, RPL31, RPL30, RPS17, FAU, RPS25, RPL22L1, RPL11) are related to viral mRNA translation (Stelzer et al., 2016). Additionally, the DAVID database (Protein interactions) associated five COVID 19 genes (RPL30, RPS17, RPS24, RPS25, and FAU) with HIV interactions (Huang, Sherman & Lempicki, 2009).
Recently, hematological malignancies (HM) patients were reported to have a more severe COVID-19 trajectory than patients with solid organ tumors (Lee et al., 2020). A significant number of the COVID 19 related genes were upregulated in various lymphomas and some multiple myeloma datasets (Fig. S9). Most of our COVID-19 pathway genes showed some correlations with immune infiltrates such as TIL and macrophages. An anti-viral immune response can have protective effects with improved survival in coronavirus infection, but excessive inflammation can be harmful (“cytokine storm”). High pro-inflammatory macrophage (M1) and low CD8+ T cells were observed in the microenvironment of severe/critical COVID-19 patients (Liao et al., 2020). Higher expression of CXCL9 in COVID-19 patients than healthy controls and higher levels of CCL4 in severe COVID-19 patients were also found (Liao et al., 2020). These are partly consistent with our data and previous knowledge on various cancers (Brune et al., 2008; Chang et al., 2013; De la Fuente López et al., 2018). Not much is known about COVID-19 and most cancers, including DLBCL pathogenesis. However, it is tempting to speculate that COVID-19 infection, together with the COVID-19 related genes, could increase macrophage polarization to M1 (hyper-inflammatory response) to worsen prognosis (He et al., 2020; Passamonti et al., 2020; Shah et al., 2020). But, the mechanism is unclear, and limited data on the topic did not permit detailed discussion. However, extensive genome-related studies are required to verify this association between COVID 19 and DLBCL; these genes could provide a basis to identify effective preventive and therapeutic strategies.
Clinical implication analysis in the GEPIA2 database showed that the core hub genes were significantly overexpressed in DLBCL. The high expressions of 14 (93%) were negatively associated with prognostic outcomes (worse OS and PFS times). These emphasize their potential role as oncogenes and could be utilized as prognostic indicators for DLBCL. The high expression of RPL11 might be associated with a favorable clinical outcome (Kawahata et al., 2020; Kayama et al., 2017). They offer unique opportunities for further investigation.
In addition to the ribosome (translation), the 46 hub genes were significantly represented in oxidative phosphorylation (OxPhos) and mitochondria inner membrane. Growing evidence suggests cancer is primarily a mitochondrial metabolic disease that exhibits altered energy production and dysregulated metabolic crosstalk (Yin et al., 2019; Norberg et al., 2017). Their inhibition has demonstrated anti-cancer efficacy (Martínez-Reyes et al., 2020; Norberg et al., 2017). Thus, with further studies, these metabolic genes could be rational targets, especially for the metabolically coupled and OxPhos-DLBCL subsets, and help understand the metabolic differences in DLBCL.
The few bioinformatics analyses on DLBCL focused on the subtypes (Huang, Liu & Shen, 2019; Zhou et al., 2020) or clinical features (Xiao, Wang & Bai, 2020). However, some dysregulated genes specific to DLBCL versus non-tumor controls cannot distinguish the subtypes (Huang, Liu & Shen, 2019). Moreover, most related studies that focused on DLBCL and non-cancer controls were based on DEGs (Huang, Liu & Shen, 2019; Luo et al., 2018) and discovered entirely different core hub genes. However, the complexity of DLBCL and the emergence of novel targeted therapies warrants more predictive personalized biomarkers for precision medicine. To our knowledge, no integrated bioinformatics analysis on DLBCL and non-tumor controls has so far been reported on the common core hub genes found and immune cells associations. Thus, our finding is novel.
One potential limitation of this study is the lack of experimental validation. However, this analysis provides a theoretical basis for our future work, which will focus on experimental verification. Second, an individual study with limited DLBCL cases was used, but the hub genes, pathways, and immune cells infiltrate identified are relevant to the pathogenesis of DLBCL and cannot be ignored. However, our results should be interpreted with caution.
Conclusions
We used the integrated bioinformatics method to highlight the critical roles of differentially co-expressed core hub genes and relevant pathways in DLBCL. We identified some immune-related core hub genes linked to DLBCL pathogenesis. The core genes’ main KEGG pathway enrichments were Ribosome and Coronavirus disease-COVID-19. Their verification in GEPIA2 showed they were reliable. Nevertheless, most of the core genes were upregulated in different cancer types and hold potential biological and clinical relevance in cancers. Thus, the identified genes could be potential targets for prognosis and therapeutic intervention in DLBCL and may provide insight into the pathogenetic mechanisms in DLBCL.
Supplemental Information
Flow diagram of the study (GSE12453). One poor-quality sample (GSM312887) was excluded.
PPI: protein-protein interaction; DEGs: differentially expressed genes; CEGs: co-expressed genes; HPA: the human protein atlas.
Gene ontology (GO) and KEGG enrichment analysis for 118 intersecting DEGs.
(A) GO analysis; the top 10 significantly enriched GO terms of intersecting DEGs, p < 0.05. (B) The top 12 significantly enriched KEGG pathways of intersecting DEGs, p < 0.05. The horizontal axis is the number of intersecting DEGs involved in the terms or pathways; the vertical axis shows the terms or pathway names. KEGG (Kyoto encyclopedia of genes and genomes).
Correlation matrix of the analyzed tumor-infiltrating immune cells in a color legend, GSE12453.
x-and y-axes both represent tumor-infiltrating immune cells. Color legend: red (positive) and blue (negative) correlations.
Protein-protein interaction (PPI) network of downregulated genes.
(A) PPI for the top 30 up-and 30 down-regulated DEGs ranked by highest log2FC at the highest confidence of 0.9. (B) PPI for all downregulated genes at high confidence of 0.7 with disconnected nodes in the network hidden (it yielded 30 nodes, 20 edges). (C) PPI of the downregulated DEGs enriched in B cell activation for GO biological processes (medium confidence, 0.4); false discovery rate, 6.29e−15).
Protein-protein interaction (PPI) network for the 3 relevant co-expressed module genes.
The PPI network of turquoise, green and dark magenta module genes at high confidence of 0.9 with disconnected nodes hidden.
Receiver operating characteristic (ROC) curve of core hub genes.
MRPS28, RPL22L1, RPL30, and RPS17 each had an AUC of 0.989. Also, CXCL9, HEBP1, RPL11, RPS21 and RPS 24 each had an AUC of 1.00. The area under curve (AUC).
Immunohistochemistry (IHC) showing lymph node expression patterns of 4 core hub genes.
The averaged protein expression levels of normal tissue (NT)-not otherwise stated (NOS) non-germinal center cells (N-GCC) were relatively lower than the expression levels in some selected tumor tissues. Q: quantity of IHC score; DLBCL: NHL high grade; LG: NHL-low grade; HD-NOS: Hodgkin’s disease-NOS; id: Patient id. Data retrieved from the human protein atlas (https://www.proteinatlas.org/).
Correlation matrix predicting core hub genes associated with tumor-infiltrating immune cells in GSE31312 dataset.
The 15 core hub genes expression levels in other tumors.
Most of the genes were upregulated in various cancer types. However, some genes were downregulated in some tumors, suggesting that the same gene may have different functions in different cancers. Data were retrieved from the Oncomine database (https://www.oncomine.org/resource/main.html).
GSEA Hallmarks enrichment analysis for the GSE12453 dataset.
Top 20 hallmark enrichment. ES, Enrichment Score; NES, normalized Enrichment Score; NOM P-val, nominal p value; FDR, false discovery rate >0.25; FWER, familywise-error rate
List of core hub genes upregulated in other tumors.
p-value < 0.01; |Log2FC| > 1. RPL30 and FAU (marked in red) were consistently upregulated in all six tumor types. THYM: Thymoma; TGCT: Testicular Germ Cell Tumors; CHOL: Cholangio carcinoma; LGG: Brain Lower Grade Glioma; GBM: Glioblastoma multiforme; PAAD: Pancreatic adenocarcinoma (http://gepia2.cancer-pku.cn/#analysis)